Loading...

AzurRx BioPharma

DB:366
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
366
DB
$49M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
366 Share Price and Events
7 Day Returns
0%
DB:366
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:366
-9.2%
DE Biotechs
-6.7%
DE Market
366 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AzurRx BioPharma (366) 0% 0% - - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on 366.
  • No trading data on 366.
Price Volatility
366
Industry
5yr Volatility vs Market
Related Companies

366 Value

 Is AzurRx BioPharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AzurRx BioPharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AzurRx BioPharma.

DB:366 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:366
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0.52%))
1.31
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.31 * 5.96%)
8.03%

Discounted Cash Flow Calculation for DB:366 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AzurRx BioPharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:366 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.03%)
2019 -13.18 Analyst x1 -12.20
2020 -17.53 Analyst x1 -15.02
2021 -22.67 Analyst x1 -17.98
2022 -11.18 Analyst x1 -8.21
2023 4.64 Analyst x1 3.15
2024 5.49 Est @ 18.31% 3.45
2025 6.20 Est @ 12.89% 3.61
2026 6.76 Est @ 9.09% 3.64
2027 7.20 Est @ 6.43% 3.59
2028 7.53 Est @ 4.57% 3.48
Present value of next 10 years cash flows $-32.48
DB:366 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $7.53 × (1 + 0.23%) ÷ (8.03% – 0.23%)
$96.64
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $96.64 ÷ (1 + 8.03%)10
$44.63
DB:366 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-32.48 + $44.63
$12.15
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $12.15 / 19.83
$0.61
DB:366 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:366 represents 0.45749x of NasdaqCM:AZRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.45749x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.61 x 0.45749
€0.28
Value per share (EUR) From above. €0.28
Current discount Discount to share price of €1.13
= -1 x (€1.13 - €0.28) / €0.28
-303.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of AzurRx BioPharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AzurRx BioPharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AzurRx BioPharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:366 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.88
NasdaqCM:AZRX Share Price ** NasdaqCM (2019-02-18) in USD $2.47
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AzurRx BioPharma.

DB:366 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AZRX Share Price ÷ EPS (both in USD)

= 2.47 ÷ -0.88

-2.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AzurRx BioPharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AzurRx BioPharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AzurRx BioPharma's expected growth come at a high price?
Raw Data
DB:366 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
12.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AzurRx BioPharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AzurRx BioPharma's assets?
Raw Data
DB:366 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.25
NasdaqCM:AZRX Share Price * NasdaqCM (2019-02-18) in USD $2.47
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:366 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AZRX Share Price ÷ Book Value per Share (both in USD)

= 2.47 ÷ 0.25

9.77x

* Primary Listing of AzurRx BioPharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AzurRx BioPharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AzurRx BioPharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AzurRx BioPharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

366 Future Performance

 How is AzurRx BioPharma expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AzurRx BioPharma expected to grow at an attractive rate?
  • AzurRx BioPharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • AzurRx BioPharma's earnings growth is expected to exceed the Germany market average.
  • Unable to compare AzurRx BioPharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:366 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:366 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 12.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:366 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:366 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 38 3 2
2022-12-31 30 -4 3
2021-12-31 0 -24 3
2020-12-31 0 -16 5
2019-12-31 0 -14 5
DB:366 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -11 -14
2018-09-30 -10 -12
2018-06-30 -9 -13
2018-03-31 -8 -12
2017-12-31 -7 -11
2017-09-30 -7 -14
2017-06-30 -7 -14
2017-03-31 -5 -15
2016-12-31 -5 -15
2016-09-30 -3 -10
2016-06-30 -4 -8
2016-03-31 -4 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AzurRx BioPharma's earnings are expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if AzurRx BioPharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:366 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from AzurRx BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:366 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.12 0.12 0.12 1.00
2022-12-31 -0.16 0.11 -0.43 2.00
2021-12-31 -0.83 -0.81 -0.85 2.00
2020-12-31 -0.61 -0.51 -0.74 5.00
2019-12-31 -0.69 -0.65 -0.74 4.00
DB:366 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.88
2018-09-30 -0.85
2018-06-30 -0.99
2018-03-31 -1.05
2017-12-31 -1.04
2017-09-30 -1.42
2017-06-30 -1.64
2017-03-31 -1.99
2016-12-31 -2.24
2016-09-30 -1.88
2016-06-30 -1.84
2016-03-31 -1.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AzurRx BioPharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AzurRx BioPharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AzurRx BioPharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

366 Past Performance

  How has AzurRx BioPharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AzurRx BioPharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AzurRx BioPharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AzurRx BioPharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AzurRx BioPharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AzurRx BioPharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AzurRx BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:366 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -13.53 8.24 4.99
2018-09-30 -11.99 7.52 3.92
2018-06-30 -12.56 8.21 3.72
2018-03-31 -11.92 7.43 3.54
2017-12-31 -11.10 7.69 2.40
2017-09-30 -14.25 7.60 2.47
2017-06-30 -14.31 6.14 2.25
2017-03-31 -15.41 5.64 2.34
2016-12-31 -14.59 4.13 2.50
2016-09-30 -9.63 2.79 1.93
2016-06-30 -8.30 3.30 1.55
2016-03-31 -6.73 3.23 1.77
2015-12-31 -5.93 3.33 1.40
2015-09-30 -6.22 3.40 1.91
2015-06-30 -5.30 3.13 1.73
2015-03-31 -3.33 2.47 1.01
2014-12-31 -2.37 1.87 1.05
2013-12-31 -1.01 0.54 0.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AzurRx BioPharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AzurRx BioPharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AzurRx BioPharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AzurRx BioPharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AzurRx BioPharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

366 Health

 How is AzurRx BioPharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AzurRx BioPharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AzurRx BioPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AzurRx BioPharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AzurRx BioPharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 18.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AzurRx BioPharma Company Filings, last reported 3 months ago.

DB:366 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.47 0.26 1.11
2018-09-30 5.53 0.00 4.43
2018-06-30 7.63 0.31 7.42
2018-03-31 1.10 0.32 0.57
2017-12-31 1.66 0.42 0.57
2017-09-30 2.80 0.34 2.95
2017-06-30 4.64 0.67 3.83
2017-03-31 1.47 0.08 0.53
2016-12-31 3.21 0.16 1.77
2016-09-30 -12.37 9.93 0.13
2016-06-30 -9.23 9.24 1.39
2016-03-31 -5.42 7.46 0.21
2015-12-31 -3.63 6.58 0.64
2015-09-30
2015-06-30 -0.14 2.93 0.24
2015-03-31 2.64 1.05 0.22
2014-12-31 2.64 1.05 0.22
2013-12-31 0.05 0.20 0.05
  • AzurRx BioPharma's level of debt (5.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (332.6% vs 5.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AzurRx BioPharma has less than a year of cash runway based on current free cash flow.
  • AzurRx BioPharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 38.9% each year.
X
Financial health checks
We assess AzurRx BioPharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AzurRx BioPharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

366 Dividends

 What is AzurRx BioPharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AzurRx BioPharma dividends.
If you bought €2,000 of AzurRx BioPharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AzurRx BioPharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AzurRx BioPharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:366 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:366 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AzurRx BioPharma has not reported any payouts.
  • Unable to verify if AzurRx BioPharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AzurRx BioPharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AzurRx BioPharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AzurRx BioPharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AzurRx BioPharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AzurRx BioPharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

366 Management

 What is the CEO of AzurRx BioPharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thijs Spoor
COMPENSATION $1,011,067
AGE 46
TENURE AS CEO 3.3 years
CEO Bio

Mr. Johan M. Spoor, also known as Thijs, has been the Chief Executive Officer and President of AzurRx BioPharma, Inc. since January 2016 and April 2015 respectively. Mr. Spoor served as the Chief Operating Officer at AzurRx BioPharma, Inc. He served as the Chief Executive Officer of FluoroPharma Medical, Inc. since February 14, 2011 until December 29, 2015 and served as its President since February 14, 2011 until October 05, 2015. Previously, Mr. Spoor served as the Chief Financial Officer of FluoroPharma Medical, Inc. until August 2012 and also served as its Chief Accounting Officer. He has 15 years of international experience in the medical industry across a variety of roles including Regulatory Affairs and New Product Development. He was the Chief Financial Officer for Sunstone BioSciences from February 2010 to September 2010. Prior to joining Sunstone BioSciences, he worked as a Consultant at Oliver Wyman from December 2008 to February 2010, focusing on helping pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform. He also spent 4 years on Wall Street at J.P. Morgan and Credit Suisse, where he covered biotechnology and medical device stocks. Mr. Spoor served as a Research Analyst of Crédit Suisse AG, Research Division. He served as an Associate of JP Morgan Chase & Co, Research Division. He was an Equity Research Analyst at J.P. Morgan from July 2007 to October 2008 and Credit Suisse from November 2005 to July 2007, covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry spending 11 years with Amersham / GE Healthcare where he worked in 7 countries in a variety of roles including setting up GMP facilities, accountability for the nuclear cardiology portfolio and as the Director of New Product Opportunities leading the PET strategic plan. He served as the Global Brand Head for Nuclear Cardiology at GE Healthcare. He served as the Chairman of AzurRx BioPharma, Inc from June 2014 to September 2015. He served as the Chairman of FluoroPharma Medical, Inc. since June 14, 2012 until December 29, 2015. Mr. Spoor served as the Chairman of MetaStat, Inc. (former Name: Photovoltaic Solar Cells Inc) from 2012 to October 15, 2014 and served as its Independent Director since April 7, 2012 until August 31, 2016. He has been an Independent Director of Atheronova Inc., since January 3, 2012. He serves as a Director of AzurRx BioPharma, Inc. He has been a Director at Protea Biosciences, Inc., since January 28, 2013 and FluoraPharma Medical Inc., since September 2010. He served as Director of FluoroPharma Medical, Inc. from February 14, 2011 to January 1, 2017. He served as a Director of Protea Biosciences Group, Inc from January 28, 2013 to August 18, 2014. He is trained as a Nuclear Pharmacist. He has been a guest lecturer at Columbia Business School, Kings College in London and the University of Newcastle in Australia. Mr. Spoor holds an MBA from Columbia University with concentrations in finance and accounting and holds a Nuclear Pharmacy Degree from the University of Toronto.

CEO Compensation
  • Thijs's compensation has increased whilst company is loss making.
  • Thijs's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AzurRx BioPharma management team in years:

2.4
Average Tenure
58
Average Age
  • The tenure for the AzurRx BioPharma management team is about average.
Management Team

Thijs Spoor

TITLE
President
COMPENSATION
$1M
AGE
46
TENURE
3.3 yrs

Maged Shenouda

TITLE
CFO & Director
COMPENSATION
$964K
AGE
54
TENURE
1.6 yrs

Daniel Dupret

TITLE
Chief Scientific Officer
COMPENSATION
$422K
AGE
62
TENURE
4.8 yrs

Mathieu Schué

TITLE
Head of Laboratory

Jim Pennington

TITLE
Chief Medical Officer
AGE
75
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the AzurRx BioPharma board of directors in years:

3.5
Average Tenure
64.5
Average Age
  • The tenure for the AzurRx BioPharma board of directors is about average.
Board of Directors

Ed Borkowski

TITLE
Chairman
COMPENSATION
$229K
AGE
60
TENURE
3.6 yrs

Thijs Spoor

TITLE
President
COMPENSATION
$1M
AGE
46

Maged Shenouda

TITLE
CFO & Director
COMPENSATION
$964K
AGE
54
TENURE
3.5 yrs

Alastair Riddell

TITLE
Director
COMPENSATION
$229K
AGE
69
TENURE
3.6 yrs

Philip Toskes

TITLE
Member of Scientific Advisory Board

Fréderic Carrière

TITLE
Member of Scientific Advisory Board

René Laugier

TITLE
Member of Scientific Advisory Board

Mark Lowe

TITLE
Member of Scientific Advisory Board

Chuck Casamento

TITLE
Director
COMPENSATION
$130K
AGE
73
TENURE
2.1 yrs

Vern Schramm

TITLE
Director
COMPENSATION
$39K
AGE
77
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Jan 19 Buy Edmund Ross Individual 02. May 18 02. May 18 20,000 €2.09 €41,765
07. Jan 19 Buy Edmund Ross Individual 27. Dec 18 31. Dec 18 119,545 €1.03 €120,942
02. Jan 19 Buy Johan Spoor Individual 28. Dec 18 28. Dec 18 38,583 €1.13 €43,653
02. Jan 19 Buy Maged Shenouda Individual 28. Dec 18 28. Dec 18 20,000 €1.15 €22,901
02. Jan 19 Buy Charles Casamento Individual 28. Dec 18 28. Dec 18 9,000 €1.23 €11,086
X
Management checks
We assess AzurRx BioPharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AzurRx BioPharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

366 News

Simply Wall St News

366 Company Info

Description

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Details
Name: AzurRx BioPharma, Inc.
366
Exchange: DB
Founded: 2014
$43,579,042
19,832,888
Website: http://www.azurrx.com
Address: AzurRx BioPharma, Inc.
Downstate Biotechnology Incubator,
Suite 304,
Brooklyn,
New York, 11226,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AZRX Common Stock Nasdaq Capital Market US USD 11. Oct 2016
DB 366 Common Stock Deutsche Boerse AG DE EUR 11. Oct 2016
Number of employees
Current staff
Staff numbers
12
AzurRx BioPharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:49
End of day share price update: 2019/02/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.